

Avastin es más:

EXPERIENCIA,
EVIDENCIA
E INNOVACIÓN

Es:

CONTROL DEL CÁNCER

ANTI-ANGIOGENESIS

La adición de Avastin a la quimioterapia
proporciona una ventaja favorable
en términos de supervivencia global^{2,5}

15

AÑOS

DESDE SU APROBACIÓN
EN COLOMBIA^{9,10}

Es:


EXPERIENCIA

PINTANDO ESPERANZA
PARA MÁS PACIENTES

Es:

EFICACIA


COMPROBADA EN 6
TIPOS DE CÁNCER^{9,10}




AVASTIN[®]
bevacizumab



OVARIO^{9,10}




AVASTIN[®]
bevacizumab

 **AVASTIN**[®]
bevacizumab



CERVIX^{9,10}

 **AVASTIN**[®]
bevacizumab

Es:

EVIDENCIA


**ESTUDIOS CLÍNICOS POSITIVOS
QUE RESPALDAN SU USO¹⁻⁸**


Es:

EVIDENCIA

**MÁS DE 6.052 PACIENTES
ENROLADOS EN LOS ESTUDIOS CLÍNICOS¹⁻⁸**


Roche




 **AVASTIN®**
bevacizumab

REGISTRO INVIMA 2016M-0004781-R1

Roche



 **AVASTIN®**
bevacizumab

REGISTRO INVIMA 2016M-0004782-R1

Referencias:

1. A study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients with Metastatic Colorectal Cancer.
2. Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer a systematic review
3. Bevacizumab plus chemotherapy contended beyond first progression in patients with metastatic colorectal cancer previously treated with Bevacizumab plus chemotherapy
4. A Study of Avastin (Bevacizumab) Added to interferon Alfa-2a (Roferon) Therapy in Patients with Metastatic Renal Cell Cancer with Nephrectomy
5. Combination Chemotherapy with or Without Bevacizumab in Treating Patients with Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer
6. A Phase 3 Trial of Bevacizumab in ovarian Cancer
7. Bevacizumab for advanced cervical cancer
8. Erlotinib Plus Bevacizumab Phase II Study in Patients with Advanced Non-Small-Cell Lung Cancer
9. Registro INVIMA 2016M-0004781-R1, RESOLUCIÓN No. 2016008809 de 14 de marzo de 2016
10. Registro INVIMA 2016M-0004782-R1, RESOLUCIÓN No. 2016033808 de 31 de agosto de 2016
11. Nejimoa1716943-Atezolizumab or list line treatment of Nonsquamous NSCLC.
12. Registro INVIMA 2019MBT-0000003, RESOLUCIÓN No. 2019056251 de 11 de diciembre de 2019.

Información para prescribir
Avastin® (Bevacizumab)
Consulte AQUÍ:



Avastin®
(Bevacizumab)

Información para uso
exclusivo del cuerpo médico.